Non-Hodgkin Lymphoma | Specialty

Immunotherapy for Follicular Lymphoma

July 20th 2016

Immunotherapy in Refractory DLBCL

July 20th 2016

PD-1 Inhibitors in Hodgkin Lymphoma

July 20th 2016

Immunotherapy Response Among Hematologic Malignancies

July 20th 2016

Immunotherapy: What is the Role in Lymphoid Cancers?

July 20th 2016

Obinutuzumab Falls Short in Phase III DLBCL Trial

July 18th 2016

Adding the anti-CD20 agent obinutuzumab (Gazyva) to CHOP chemotherapy in the frontline setting did not improve progression-free survival compared with the standard regimen of rituximab (Rituxan) plus CHOP in patients with diffuse large B-cell lymphoma.

Preliminary Data for Duvelisib in Indolent NHL

June 29th 2016

PI3K-Targeted Therapy for Follicular Lymphoma

June 29th 2016

Treatment of Follicular Lymphoma

June 29th 2016

Encouraging Early Data for Novel PI3K Inhibitors

June 29th 2016

Duvelisib in Relapsed/Refractory CLL

June 29th 2016

Role of PI3K-Targeted Therapy in CLL

June 29th 2016

Treating Chronic Lymphocytic Leukemia

June 29th 2016

Dr. Christian Gisselbrecht on Outcomes of Relapsed DLBCL

June 17th 2016

Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).

Duvelisib Hits Endpoint But Misses Expectations in Phase II iNHL Study

June 17th 2016

Single-agent duvelisib demonstrated an overall response rate of 46% for patients with indolent non-Hodgkin lymphoma, which successfully met the primary endpoint for the phase II DYNAMO study but not investor expectations.

Obinutuzumab Approved in Europe for Follicular Lymphoma

June 16th 2016

The European Commission approved obinutuzumab (Gazyvaro, EU; Gazyva, US) for use in combination with bendamustine, followed by maintenance obinutuzumab, as a treatment for patients with follicular lymphoma who are refractory to or progress on a single-agent rituximab (MabThera) or rituximab-containing regimen.

Dr. Wojciech Jurczak on MOR208 in Non-Hodgkin's Lymphoma

June 11th 2016

​Wojciech Jurczak, MD Head of Lymphoma, Department of Hematology, Jagiellonian University, Kopernika, Poland, discuses a subgroup analyses of diffuse large b-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).

Upfront Obinutuzumab Delays Progression in Follicular Lymphoma

May 27th 2016

Combining obinutuzumab (Gazyva) with chemotherapy in the first-line setting significantly reduced the risk of disease progression versus rituximab (Rituxan) plus chemotherapy in patients with follicular lymphoma.

Dr. Leonard on Treating Relapsed Patients With Follicular Lymphoma

May 12th 2016

John P. Leonard, MD, medical oncology, Weill Cornell Medicine and New-York Presbyterian, discusses treatment considerations for relapsed patients with follicular lymphoma.

Combination Regimens on the Rise in Mantle Cell Lymphoma

May 6th 2016

Michael E. Williams, MD, discusses emerging regimens on the horizon in mantle cell lymphoma, the potential of BCL-2 inhibition, and whether chemotherapy can be removed entirely from the treatment landscape.